close

Agreements

Date: 2018-09-10

Type of information: Nomination

Compound: member of the board of directors

Company: Halozyme Therapeutics (USA - CA)

Therapeutic area: Cancer - Oncology

Type agreement: nomination

Action mechanism:

Disease:

Details:

  • • On September 10, 2018, Halozyme Therapeutics, a biotechnology company developing novel oncology and drug-delivery therapies, announced the appointment of Bernadette Connaughton to its board of directors. Ms. Connaughton brings more than 30 years of global strategic, commercial and biopharmaceutical industry expertise to the board. Ms. Connaughton has spent her career at BMS building a consistent track record of achieving sales growth, improving profitability and transforming operational models. She most recently served as president Intercontinental, including China, Latin America, Central and Eastern Europe and Middle East. In this position, she developed the multi-year strategy for the successful commercialization of a number of oncology, virology and immunology products, including Opdivo®, Yervoy®, Sprycel®, Daklinza® and Orencia®.
  • She has held other senior leadership positions at BMS including president, European Markets, Canada and Australia; president, Intercontinental; and president, Japan, Pacific Rim, Australia and Canada; senior vice president, Cardiovascular and Metabolic Business Unit, U.S.; and senior vice president, Primary Care Marketing, U.S.
  • Ms. Connaughton was a member of the board of directors of Visterra, a private clinical stage biotechnology company recently acquired by Otsuka. She also previously served on the European Federation of Pharmaceutical Industry Association, Patient Access and European Markets Committees. She received her Bachelor of Arts from Johns Hopkins University and her Master of Business Administration from The Wharton School, University of Pennsylvania.

Financial terms:

Latest news:

Is general: Yes